• Wiley Online Library will be disrupted on 26 May from 10:00-12:00 BST (05:00-07:00 EDT) for essential maintenance

Lactation inhibition by a single injection of a new depot-bromocriptine

  1. J. A. M. KREMER1,
  2. R. ROLLAND1,*,
  3. P. F. M. VAN DER HEIJDEN1,
  4. L. A. SCHELLEKENS1,
  5. M. B. J. G. VOSMAR1,
  6. I. LANCRANJAN2

Article first published online: 19 AUG 2005

DOI: 10.1111/j.1471-0528.1990.tb02524.x

Issue

BJOG: An International Journal of Obstetrics & Gynaecology

BJOG: An International Journal of Obstetrics & Gynaecology

Volume 97, Issue 6, pages 527–532, June 1990

Additional Information

How to Cite

KREMER, J. A. M., ROLLAND, R., VAN DER HEIJDEN, P. F. M., SCHELLEKENS, L. A., VOSMAR, M. B. J. G. and LANCRANJAN, I. (1990), Lactation inhibition by a single injection of a new depot-bromocriptine. BJOG: An International Journal of Obstetrics & Gynaecology, 97: 527–532. doi: 10.1111/j.1471-0528.1990.tb02524.x

Author Information

  1. 1

    Department of Obstetrics and Gynaecology, St. Radboud University Hospital, Nijmegen, The Netherlands

  2. 2

    Department of Neuroendocrinology, Sandoz Ltd, Basel, Switzerland

* Prof. Dr. R. Rolland MD PhD, Department of Obstetrics and Gynaecology, University of Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands

Publication History

  1. Issue published online: 19 AUG 2005
  2. Article first published online: 19 AUG 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (475K)

Summary. Recently, long-acting injectable forms of bromocriptine have become available for the prevention of lactation. The first developed depot-form was very effective, but had the disadvantage of a slowly metabolized carrier. We investigated the pharmacokinetics, efficacy, tolerance and safety of 40 and 50 mg of a new rapidly eliminated depotform in 61 postpartum women. Bromocriptine rapidly increased after injection and prolactin was effectively suppressed during the studyperiod of 60 days. Overall efficacy was very good or good in 98% and no rebound lactation occurred. Sixteen women experienced side effects. Tolerance at the injection site was good and safety tests did not show abnormalities. There were no differences between the two dosages. We conclude that this new depot-bromocriptine is a safe, well tolerated and effective drug in the suppression of prolactin and the prevention of postpartum lactation.

Get PDF (475K)